Entera Bio Ltd. (ENTX) Stock

NASDAQ: ENTXDevelops oral formulations of drugs and biologics, leveraging its proprietary drug delivery platform to improve treatment outcomes.

Entera Bio stock price chart

ENTX interactive chart →

ENTX stock quote & key statistics

Entera Bio earnings per share

Income →
Earnings per share

Entera Bio revenue & net income

Income →
RevenueNet income

Entera Bio annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$42,000-$11.4M-$0.25
FY2024$181,000-$9.5M-$0.25
FY2023$14,000-$8.9M-$0.31
FY2022$134,000-$13.1M-$0.45
FY2021$571,000-$12.2M-$0.90

Fiscal year ending December 31. Source: company filings via EODHD.

About Entera Bio Ltd.

Entera Bio Ltd., a clinical-stage biopharmaceutical firm, specializes in advancing and commercializing orally delivered large molecule therapeutics to address significant medical needs.

Leading its portfolio are EB612 and EB613. EB612 is currently in Phase II clinical trials for hypoparathyroidism, while EB613 has completed Phase II trials for osteoporosis and is in Phase I trials for non-union fractures treatment. Additionally, Entera Bio has forged a strategic research collaboration and license agreement with Amgen Inc., focusing on developing clinical candidates targeting inflammatory diseases and other critical conditions.

Founded in 2009 and headquartered in Jerusalem, Israel, Entera Bio Ltd. continues to innovate at the forefront of oral biologic drug delivery. The company's commitment to pioneering advancements in therapeutic solutions underscores its mission to improve patient outcomes globally.

Entera Bio stock FAQ

What is the Entera Bio stock ticker symbol?

Entera Bio Ltd. trades on the NASDAQ under the ticker symbol ENTX.

What sector and industry is Entera Bio in?

Entera Bio Ltd. is classified in the Healthcare sector, Biotechnology industry.

How many employees does Entera Bio have?

Entera Bio Ltd. has about 20 full-time employees.

What were Entera Bio's revenue and earnings last fiscal year?

Entera Bio reported revenue of $42,000 and net income of -$11.4M in fiscal 2025, with earnings per share of -$0.25. Revenue declined 76.8% from the prior year.

When did Entera Bio go public?

Entera Bio stock began trading on June 28, 2018.

Biotechnology stocks

All Healthcare stocks →